Zacks Research Equities Analysts Cut Earnings Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Equities researchers at Zacks Research decreased their Q2 2026 earnings per share (EPS) estimates for Apellis Pharmaceuticals in a report released on Wednesday, September 25th. Zacks Research analyst R. Department now anticipates that the company will earn $0.01 per share for the quarter, down from their previous estimate of $0.02. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.34) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ FY2026 earnings at $0.20 EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.03. The business had revenue of $199.70 million during the quarter, compared to the consensus estimate of $190.89 million. Apellis Pharmaceuticals had a negative return on equity of 138.32% and a negative net margin of 52.99%. The company’s revenue was up 110.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.02) earnings per share.

Several other equities research analysts also recently weighed in on the company. HC Wainwright decreased their price objective on Apellis Pharmaceuticals from $92.00 to $83.00 and set a “buy” rating for the company in a report on Friday, August 2nd. The Goldman Sachs Group upped their price target on Apellis Pharmaceuticals from $66.00 to $74.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. UBS Group cut their price target on Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Piper Sandler started coverage on Apellis Pharmaceuticals in a research note on Friday, May 31st. They set a “neutral” rating and a $46.00 price target for the company. Finally, Robert W. Baird cut their price target on Apellis Pharmaceuticals from $96.00 to $92.00 and set an “outperform” rating for the company in a research note on Monday, September 23rd. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $70.20.

Apellis Pharmaceuticals Price Performance

APLS stock opened at $29.47 on Friday. The company has a market capitalization of $3.58 billion, a P/E ratio of -8.52 and a beta of 0.88. Apellis Pharmaceuticals has a twelve month low of $29.28 and a twelve month high of $73.80. The business has a 50 day simple moving average of $37.01 and a 200-day simple moving average of $42.71. The company has a current ratio of 5.08, a quick ratio of 4.18 and a debt-to-equity ratio of 1.73.

Insider Activity

In other news, Director A. Sinclair Dunlop sold 37,000 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the completion of the transaction, the director now owns 100,000 shares in the company, valued at $3,623,000. The sale was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 6.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. HighVista Strategies LLC increased its position in shares of Apellis Pharmaceuticals by 4.1% in the second quarter. HighVista Strategies LLC now owns 7,566 shares of the company’s stock valued at $290,000 after buying an additional 300 shares in the last quarter. Amalgamated Bank boosted its stake in shares of Apellis Pharmaceuticals by 5.4% during the second quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock valued at $268,000 after acquiring an additional 359 shares during the last quarter. Simplicity Wealth LLC boosted its stake in shares of Apellis Pharmaceuticals by 0.6% during the second quarter. Simplicity Wealth LLC now owns 78,746 shares of the company’s stock valued at $3,021,000 after acquiring an additional 499 shares during the last quarter. Future Financial Wealth Managment LLC acquired a new stake in shares of Apellis Pharmaceuticals during the first quarter valued at $29,000. Finally, Oppenheimer Asset Management Inc. boosted its stake in shares of Apellis Pharmaceuticals by 8.3% during the first quarter. Oppenheimer Asset Management Inc. now owns 8,694 shares of the company’s stock valued at $511,000 after acquiring an additional 664 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).